Folyóiratcikkek tallózása szerző szerint "Kéri, György"

1-20 / 20

Acid-base profiling of imatinib (Gleevec) and its fragments

Szakács, Zoltán; Béni, Szabolcs; Varga Z,; Őrfi, László; Kéri, György; Noszál, Béla (2005)

The site-specific basicities of imatinib (Gleevec, a new signal transduction inhibitor drug of chronic myeloid leukemia) and two of its fragment compounds were quantitated in terms of protonation macroconstants, microconstants, ...
Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy.

Torka R,; Pénzes, Kinga; Gusenbauer S,; Baumann C,; Szabadkai I,; Őrfi, László; Kéri, György (2014)

The Axl receptor tyrosine kinase (RTK) has been established as a strong candidate for targeted therapy of cancer. However, the benefits of targeted therapies are limited due to acquired resistance and activation of alternative ...
Anticytolytic Screen Identifies Inhibitors of Mycobacterial Virulence Protein Secretion

Jan Rybniker; Jeffrey M Chen; Claudia Sala; Ruben C Hartkoorn; Anthony Vocat; Andrej Benjak; Stefanie Boy-Röttger; Ming Zhang; Rita Székely; Zoltán Greff; Őrfi, László; István Szabadkai; János Pató; Kéri, György; Stewart T Cole (2014)
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells

Pénzes, Kinga; Baumann C,; Szabadkai I,; Őrfi, László; Kéri, György (2014)
Connective tissue growth factor is a new ligand of epidermal growth factor receptor

Rayego-Mateos S,; Rodrigues-Díez R,; Morgado-Pascual JL,; Rodrigues Díez RR,; Mas S,; Kéri, György (2013)

Chronic kidney disease is reaching epidemic proportions worldwide and there is no effective treatment. Connective tissue growth factor (CCN2) has been suggested as a risk biomarker and a potential therapeutic target for ...
Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing

H K Ho,; Németh, Gábor; Y R Ng,; E Pang,; C Szántai-Kis,; Zsákai, Lilian; Szokol, Bálint; Baska, Ferenc; Őrfi, László; Kéri, György (2013)

Fibroblast growth factor receptor-4 (FGFR4) is a tyrosine kinase with a range of important physiological functions. However, it is also frequently mutated in various cancers and is now generating significant interest as a ...
Discovery and biological evaluation of novel dual EGFR/c-Met inhibitors

Szokol, Bálint; Gyulavári, Pál; Kurkó Ibolya,; Baska, Ferenc; Szántai-Kis Csaba,; Peták, István; Pénzes, Kinga; Őrfi, László; Vántus, Tibor; Kéri, György (2014)
Effect of pulsed electromagnetic fields on endoplasmic reticulum stress

Keczan E; Kéri, György; Bánhegyi, Gábor; Stiller, Ibolya (2016)

The maintenance of protein homeostasis in the endoplasmic reticulum (ER) is crucial in cell life. Disruption of proteostasis results in ER stress that activates the unfolded protein response (UPR); a signalling network ...
Metformin Attenuates Palmitate-Induced Endoplasmic Reticulum Stress, Serine Phosphorylation of IRS-1 and Apoptosis in Rat Insulinoma Cells

Simon-Szabó, Laura; Kokas M; Mandl, József; Kéri, György; Csala, Miklós (2014)

Lipotoxicity refers to cellular dysfunctions caused by elevated free fatty acid levels playing a central role in the development and progression of obesity related diseases. Saturated fatty acids cause insulin resistance ...
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Brauswetter, Diána; Gurbi, Bianka; Varga, Attila; Varkondi E; Schwab R; Bánhegyi, Gábor; Fabian O; Kéri, György; Vályi-Nagy, István; Petak I (2017)

Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream target MEK could be ...
Mycobacterium tuberculosis ellenes hatoanyagok fejlesztese es szerkezet-hatas osszefuggeseinek vizsgalata.

Baska, Ferenc; Szekely ER,; Szantai-Kis C,; Banhegyi P,; Hegymegi-Barakonyi, Bálint; Zsákai, Lilian; Kéri, György; Őrfi, László (2013)

Tuberculosis is considered to be one of the major health problem not only in the less developed countries but in the economically developed countries as well. Roughly one third of the world's population are infected with ...
NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling

Barman SA,; Chen F,; Su Y,; Dimitropoulou C,; Wang Y,; Őrfi, László; Kéri, György (2014)
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors

Baska, Ferenc; Szabadkai István,; Sipos, Anna; Breza Nóra,; Szántai-Kis Csaba,; Kékesi, László; Nemes, Zoltán; Baska, Ferenc; Kéri, György; Őrfi, László (2014)
Potencialis antitumor hatasu FGFR inhibitorok fejlesztese.

Zsákai, Lilian; Nemeth G,; Szantai-Kis C,; Greff Z,; Horvath Z,; Szokol, Bálint; Baska, Ferenc; Őrfi, László; Kéri, György (2013)

Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great ...
Protein Kinase C Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation

E Damaskopoulou,; Kéri, György; V Jacob,; R Lazzarini,; S Cataldi,; Őrfi, László (2013)
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.

Kékesi, László; Sipos, Anna; Németh, Gábor; Pato J,; Breza N,; Baska, Ferenc; Őrfi, László; Kéri, György (2013)

A series of novel pyrido[2,3-b]pyrazines were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical Library were tested in phenotypic assays ...
Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors

Németh Gábor,; Greff Zoltán,; Sipos Anna,; Varga Zoltán,; Székely Rita,; Mártonffyné Jászay, Zsuzsa; Béni, Szabolcs; Nemes, Zoltán; Minárovits, János; Kéri, György; Őrfi, László (2014)
Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells

Murányi, József; Gyulavári, Pál; Varga, Attila; Bökönyi G,; Tanai H,; Vántus, Tibor; Ludányi, Krisztina; Mező, Gábor; Kéri, György (2016)

Targeted tumour therapy is the focus of recent cancer research. Gonadotropin-releasing hormone (GnRH) analogues are able to deliver anticancer agents selectively into tumour cells, which highly express GnRH receptors. ...
The Inflammatory Kinase MAP4K4 Promotes Reactivation of Kaposi's Sarcoma Herpesvirus and Enhances the Invasiveness of Infected Endothelial Cells

Haas DA; Bala K; Büsche G; Weidner-Glunde M; Santag S; Kati S; Gramolelli S; Damas M; Dittrich-Breiholz O; Kracht M; Rückert J; Varga Z; Kéri, György; Schulz TF (2013)

Kaposi's sarcoma (KS) is a mesenchymal tumour, which is caused by Kaposi's sarcoma herpesvirus (KSHV) and develops under inflammatory conditions. KSHV-infected endothelial spindle cells, the neoplastic cells in KS, show ...
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

Győrffy, Balázs; Giulia Bottai,; Jacqueline Lehmann-Ch,; Kéri, György; Őrfi, László (2014)

Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance ...

1-20 / 20

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban
Ebben a gyűjteményben

Hozzáférésem

Bejelentkezés

Folyóiratcikkek tallózása szerző szerint "Kéri, György"

DSpace/Manakin Repository

Folyóiratcikkek tallózása szerző szerint "Kéri, György"

Keresés

Tallózás

Teljes repozitórumban

Ebben a gyűjteményben

Hozzáférésem